How long can a patient with malignant peritoneal mesothelioma survive?

Malignant mesothelioma is a highly aggressive tumor originating from the mesothelial cells lining the pleura, peritoneum, and pericardial cavity. It is a difficult-to-treat malignancy with a high degree of malignancy; diagnosis and treatment are challenging, resulting in generally short survival times. So, how long can patients with peritoneal malignant mesothelioma survive?

How Long Can Patients with Peritoneal Malignant Mesothelioma Survive?

Patients with peritoneal malignant mesothelioma typically survive approximately three to six months; however, the exact survival duration is not fixed and must be assessed individually based on the patient’s specific clinical condition. Peritoneal malignant mesothelioma is a primary tumor of the peritoneum (not the pleura, as erroneously stated in the original text), and it is classified into focal and diffuse subtypes. Among these, diffuse malignant mesothelioma carries one of the poorest prognoses among thoracic malignancies. Most patients are aged between 40 and 70 years, with a higher incidence in males than females. Generally, patients with peritoneal malignant mesothelioma survive about six months—this duration depends significantly on the treatment modality employed.

Timely treatment of peritoneal malignant mesothelioma is essential and may prolong survival. Prognosis for this malignancy depends on both the patient’s overall health status and the appropriateness and timeliness of therapeutic intervention. If a patient maintains a positive and optimistic attitude and receives prompt, appropriate treatment, survival may exceed six months. Conversely, if the patient experiences severe depression and treatment is delayed or improperly administered, survival may be reduced to approximately three months.

Peritoneal malignant mesothelioma (abbreviated as PMM—not MPM, which refers to malignant pleural mesothelioma) is a primary neoplasm arising from the peritoneal mesothelium and may present as either localized or diffuse disease. Diffuse PMM is associated with one of the worst prognoses among peritoneal malignancies. Most patients are aged 40–70 years, with a male predominance. Overall, median survival for PMM is approximately six months. We hope this information is helpful!